 Analysts at HC Wainwright initiated coverage on shares of Cortexyme NASDAQ:CRTX in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a buy rating and a 76.00 price target on the biopharmaceutical companys stock. HC Wainwrights target price suggests a potential upside of 50.50 from the stocks current price. ... 